May 14, 2020
U.S. Centers for Medicare & Medicaid Services (CMS) Proposes Extending New Technology Add-on Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa® for Third Year
May 11, 2020
Portola Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
Mar 16, 2020
Portola Pharmaceuticals Announces Results Demonstrating Andexxa® was Associated with Lowest Rate of Mortality in Patients with Multiple Types of Factor Xa Inhibitor-Related Bleeds
Mar 05, 2020
New Data Demonstrates Andexxa® Can Provide a Net Cost Reduction for the Treatment of Intracranial Hemorrhage Associated with Oral Factor Xa Inhibitors
Jan 09, 2020
Portola Announces Preliminary Full Year 2019 Andexxa Global Net Revenues of Approximately $111 Million
Nov 06, 2019
Portola Pharmaceuticals to Present Multiple Abstracts at the 61st American Society of Hematology (ASH) Annual Meeting
Nov 05, 2019
Global Anticoagulant Reversal Drugs Market Report 2019: Rise of AF in Aging Populations, Increase in the Prevalence of ICH and GI Hemorrhages, NTAP Status for Specific Drugs
Oct 28, 2019
Portola Pharmaceuticals Presents New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Acute Gastrointestinal Bleeding
Aug 07, 2019
Portola Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Aug 06, 2019
Portola Launches European Sales of Ondexxya® (Andexanet Alfa) with First Orders in Europe
Aug 05, 2019
U.S. Centers for Medicare and Medicaid Services (CMS) Increases New Technology Add-On Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa
Apr 18, 2019
Anticoagulants Reversal Drugs - Global Industry Outlook to 2026: The Approval of Blockbuster Drugs in Recent Years, and a Strong Pipeline, is Driving Growth
Mar 27, 2019
Anticoagulant Reversal Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026
May 24, 2018
AGC Biologics Cleared for Commercial Manufacture of Portola's FDA-Approved Andexxa®